« Back
Home /
Cynomolgus CD30/TNFRSF8 Protein (CD3-CM130)

Cynomolgus CD30/TNFRSF8 Protein (CD3-CM130)

Item no.	CD3-CM130-500UG
Manufacturer	KactusBio
Amount	500 ug
Quantity options	100 ug 500 ug
Category	Oncology By Cell Type Hematology Leukemia Lymphoma Peptides & Proteins Recombinant Proteins Mesotheliom
Type	Proteins Recombinant
Format	Lyophilized
Specific against	Monkey (Cynomolgus, Simian)
Host	HEK293
Conjugate/Tag	HIS
Purity	> 95% as determined by Bis-Tris PAGE;> 95% as determined by HPLC
Formula	Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Sequence	Ala27-Pro394
ECLASS 10.1	32160409
ECLASS 11.0	32160409
UNSPSC	12352202
Alias	CD30,CD30KI-1,CD30L receptor,TNFRSF8,D1S166EKi-1,CD30KI-1
Shipping Condition	Room temperature
Available
Specificity	Cynomolgus
Manufacturer - Type	Recombinant Protein
Manufacturer - Targets	CD30/TNFRSF8
Manufacturer - Conjugate / Tag	C-His
Shipping Temperature	Shipped at ambient temperature.
Storage Conditions	-20 to -80°C for 12 months as supplied from date of receipt.；-80°C for 3 months after reconstitution.；Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Molecular Weight	The protein has a predicted MW of 39.86 kDa. Due to glycosylation, the protein migrates to 75-105 kDa based on Bis-Tris PAGE result.
Description	Recombinant Cynomolgus CD30/TNFRSF8 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Ala27-Pro394.
Background	The transmembrane receptor CD30 (TNFRSF8) and its ligand CD30L (CD153, TNFSF8) are members of the tumor necrosis factor (TNF) superfamily and display restricted expression in subpopulations of activated T-and B-cells in nonpathologic conditions. CD30 expression is upregulated in various hematological malignancies, including Reed-Sternberg cells in Hodgkin's disease (HD), anaplastic large cell lymphoma (ALCL) and subsets of Non-Hodgkin's lymphomas (NHLs).
Endotoxin	Less than 1 EU per μg by the LAL method.
Formulation	Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitution	Dissolve the lyophilized protein in distilled water. It is recommended to resuspend at 0.5 mg/mL if the lyophilized powder is 100 μg or less, at 1mg/ml for 500μg or 1mg lyophilized powder. Do not mix by vortex or vigorous shaking.
Biotinylated	no

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

CD3-CM130-500UG-datasheet.pdf

CD3-CM130-500UG-safety-datasheet.pdf